Replies to post #408536 on Amarin Corp Plc (AMRN)

[Tatsumaki]

short-cutting the entire lengthy marketing regulatory approval / reimbursement / budget allocation / sales processes worldwide

That whole process is huge money to the administrators of the approval process in various application fees, consultant fees, legal fees, lobbyists salaries and under the table kick backs. Regulators do not short change themselves by allowing "short cuts".

[jfmcrr]

QUOTE..."Vascepa has no market value on its own. Its sole value resides rather in a reformulation of the molecule so that what gets sold is a new improved “Statin+” rather than Vascepa, thereby short-cutting the entire lengthy marketing regulatory approval / reimbursement / budget allocation / sales processes worldwide – processes that can be hindered by a variety of geopolitical, financial, economic, generic competition and bureaucratic factors.
Only a BP selling a statin can integrate this molecule into its product and ESTABLISHED market."

This is not my experience nor that of others who post (have posted) here. That said, at this time other applications are ancillary to the center ring CVD indication.